MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: Cellvizio technology platform presented in multiple programs at Japan gastroenterological endoscopy society meeting

Transparency directive : regulatory news

28/05/2015 17:45

Press release

   CELLVIZIO TECHNOLOGY PLATFORM PRESENTED IN MULTIPLE PROGRAMS AT JAPAN
               GASTROENTEROLOGICAL ENDOSCOPY SOCIETY MEETING

* Leading clinicians to highlight applications of Cellvizio confocal laser
    endomicroscopy during the world's leading medical meeting focused on
                                  endoscopy.

PARIS, May 28, 2015 - Mauna Kea Technologies (NYSE Euronext: MKEA,
FR0010609263), inventor of Cellvizio(r), the multidisciplinary confocal laser
endomicroscopy platform, announced today that the Company's Cellvizio technology
platform will be highlighted in multiple programs during the 89th Congress of
the Japan Gastroenterological Endoscopy Society (JGES), being held May 29-31 in
Nagoya, Japan.

"We are very pleased to see the strong emergence of Confocal Laser
Endomicroscopy in Japan with the work of leading physicians being presented this
year at JGES," said Ichiro Hirata, M.D., Ph.D., President of the 89th Congress
of the Japan Gastroenterological Endoscopy Society and Professor of Medicine and
Gastroenterology, Fujita Health University, School of Medicine. "There are
multiple applications of this advanced technology that are very promising for
gastroenterology and we look forward to seeing more and more important
publications in the near future."

The goals of the JGES are to promote fundamental and clinical research in the
field of gastroenterological endoscopy and to contribute to improvements in
human healthcare in Japan and worldwide through academic research. JGES
maintains a strong focus on advances in the diagnosis, treatment and prevention
of gastrointestinal diseases (primarily gastroenterological cancer) in addition
to development of endoscopic devices. During the 2015 JGES Congress, presenters
will provide updates on a range of recent clinical developments involving use of
Cellvizio confocal laser endomicroscopy, including:

* A Keynote Lecture in the JGES Core Session on the "Clinical benefits of
  optical biopsy with endomicroscopy" by Dr Jean-François Rey, Arnault Tzanck
  Institute in Saint-Laurent du Var, France;

* A lecture on "Endoscopic Ultrasound-Guided needle-Based Confocal Laser
  Endomicroscopy for Diagnosis of Pancreatic Lesions" by Pr Pradermchai Kongkam,
  Chulalongkorn University, Bangkok, Thailand;

* A lecture on "Experience of probe-based confocal laser endomicroscopy for the
  diagnosis of biliary strictures", by Dr Senju Hashimoto, Dept. of Liver,
  Biliary Tract and Pancreas Diseases, Fujita Health University, Toyoake, Japan

* 4 additional lectures on the use of pCLE for gastric tumor, duodenum and
  colonic lesions.

* A Luncheon Seminar on "next-generation diagnostics using probe-based Confocal
  Laser Endomicroscopy" with Pr. Hisao Tajiri, Professor in the dept. of
  Innovative Interventional Endoscopy Research, The Jikei University School of
  Medicine, Tokyo and President of the Japan Gastroenterological Endoscopy
  Society; Pr. Helmut Neumann, Erlangen University Hospital and Dr Ken Ohata,
  chief of Endoscopy, NTT Kanto Medical Center, Tokyo, Japan.

"JGES is one of the oldest and most influential gatherings for G! endoscopy in
the world, and the strong presence for Cellvizio at the meeting this year is
another reflection of the rapidly growing interest in this technology in Japan
and throughout Asia," Sacha Loiseau added. "We are especially pleased that so
many leading researchers and clinicians in Japan have chosen to highlight recent
research related to the impact of Cellvizio in the dia gnosis of many G! cancers
and conditions, including pancreatic and biliary pathologies."

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on leading
innovation in endomicroscopy and optical biopsy. The company designs, develops
and markets innovative tools to visualize and detect cell abnormalities in real
time during standard gastrointestinal and pulmonary endoscopy procedures. The
company's flagship product, Cellvizio(r), a probe needlebased Confocal Laser
Endomicroscopy (pCLE/nCLE) system, provides physicians and researchers with
high-resolution cellular imaging of internal tissues. Large-scale,
international, multi-center clinical trials have demonstrated Cellvizio's
ability to help physicians to more accurately detect early forms of diseases and
make immediate treatment decisions. Designed to help physicians in their
diagnoses, provide patients with better treatment and reduce hospital costs, the
Cellvizio system can be used with virtually any endoscope. Cellvizio has 510(k)
clearance from the United States Food and Drug Administration and CE Marking in
the European Union for use in the gastrointestinal tract and the urinary and
respiratory systems, for endoscopic exploration of the biliary and pancreatic
ducts and for fine-needle aspiration procedures. Cellvizio has also obtained
SFDA regulatory approval in China and MHLW approval in Japan.

For further information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies
Eric Cohen
Vice President Finance
Tél. : +33 (0)1 70 08 09 70
investor-vpf@maunakeatech.com

France & Europe
NewCap - Investor Relations
Florent Alba / Pierre Laurent
Tél. : +33 (0)1 44 71 94 94
maunakea@newcap.fr

United States
Berry & Company Public Relations
Bill Berry
Tel: +1 212 253 8881
bberry@berrypr.com

MAUNA KEA TECHNOLOGIES's latest news

25/04/2024 20:50

MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: Cellvizio technology platform presented in multiple programs at Japan gastroenterological endoscopy society meeting

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories